23
Participants
Start Date
January 23, 2018
Primary Completion Date
March 28, 2022
Study Completion Date
July 28, 2025
PF-06939926
"Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter.~Subjects will receive a single intravenous infusion of one of 2 dose levels."
Duke Neurology, Durham
Duke University Medical Center, Lenox Baker Children's Hospital, Durham
Biospecimen Repository & Processing Core - BPRC, Durham
Duke Cardiovascular Magnetic Resonance Center, Durham
Duke Children's Hospital & Health Center, Durham
Duke University Hospital Investigational Drug Services (IDS) Pharmacy, Durham
CCTS Clinical Research Center, Salt Lake City
University of Utah Imaging and Neurosciences Center, Salt Lake City
University of Utah Hospital & Clinics Investigational Drug Services, Salt Lake City
University of Utah Hospital, Salt Lake City
Primary Children's Hospital, Salt Lake City
University of Utah Clinical Neurosciences Center, Salt Lake City
MRI Research Center, Los Angeles
Reed Neurological Research Center, Los Angeles
Ronald Reagan UCLA Medical Center (Investigational Drug Section), Los Angeles
Ronald Reagan UCLA Medical Center - Interventional Radiology, Los Angeles
Ronald Reagan UCLA Medical Center Drug Information Center, Los Angeles
UCLA (David Geffen School of Medicine), Los Angeles
UCLA Children's Heart Center, Los Angeles
UCLA Mattel Children's Hospital, Los Angeles
UCLA Medical Center, Los Angeles
UCLA Outpatient Surgery Center, Los Angeles
Lead Sponsor
Pfizer
INDUSTRY